Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2025 | $51.00 | Outperform | Mizuho |
| 11/20/2024 | $65.00 | Outperform | Raymond James |
| 8/22/2024 | $55.00 | Overweight | Wells Fargo |
| 6/26/2024 | Overweight | Piper Sandler | |
| 6/24/2024 | Buy | TD Cowen |
Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 daysTX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions ("LVEF"), including LVEF≥50% and LVEF 41-49% WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic") today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in pat
Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF")Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, SerbiaPart B of the TX45 Phase 1b trial initiated in March with topline results expected in the second half of 2025Ongoing TX45 APEX Phase 2 trial continues to enroll with topline results expected in 2026Cash and cash equivalents were $306.2 million as of March 31, 2025, including
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care Conference Date:Thursday, May 15th, 2025Time:9:20am PDTFormat:Corporate PresentationPresenter:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link The
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel
Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech
Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00
Raymond James initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $65.00
Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
424B3 - Tectonic Therapeutic, Inc. (0001681087) (Filer)
SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)